Standout Papers

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — Unite... 2023 2026 2024154
  1. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 (2023)
    Michael Melgar, Amadea Britton et al. MMWR Morbidity and Mortality Weekly Report
  2. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 (2023)
    Katherine E. Fleming-Dutra, Jefferson M. Jones et al. MMWR Morbidity and Mortality Weekly Report
  3. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 (2023)
    Jefferson M. Jones, Katherine E. Fleming-Dutra et al. MMWR Morbidity and Mortality Weekly Report
  4. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 (2023)
    Ruth Link‐Gelles, Allison Avrich Ciesla et al. MMWR Morbidity and Mortality Weekly Report
  5. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 (2024)
    Amadea Britton, Lauren E. Roper et al. MMWR Morbidity and Mortality Weekly Report

Citation Impact

16 standout
Sub-graph 1 of 8

Citing Papers

mRNA vaccines for infectious diseases — advances, challenges and opportunities
2024 Standout
Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024
2024 Standout
4 intermediate papers

Works of Lauren E. Roper being referenced

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
2023 Standout
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022
2022

Author Peers

Author Infectious Diseases Epidemiology Health PRM Last Decade Papers Cites
Lauren E. Roper 330 482 162 168 14 717
Urmi Das 14 334
W. Bernal 20 190 18 4 264
Jay Peck 16 276
John J. Stasik 14 48 160 41 1.1k
R.L. Bradshaw 23 264

All Works

Loading papers...

Rankless by CCL
2026